Download PDF
Semin Thromb Hemost 2020; 46(07): 789-795
DOI: 10.1055/s-0040-1714273
Commentary

Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19

Ashkan Hashemi
1   Department of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
,
Mahesh V. Madhavan
2   Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York
3   Clinical Trials Center, Cardiovascular Research Foundation, New York, New York
,
Behnood Bikdeli
3   Clinical Trials Center, Cardiovascular Research Foundation, New York, New York
4   Section of Vascular Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
5   Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut
› Author Affiliations
› Further Information
   Permissions and Reprints

Coronavirus disease-2019 (COVID-19) is an acute viral syndrome caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has resulted in a global pandemic.[1] [2] The disease can affect a multitude of organ systems in the body.[3] Dysregulation of hemostatic pathways, evidenced by laboratory and clinical data, plays an important role in morbidity and mortality related to COVID-19. Various forms of thrombosis, from thrombotic microangiopathy to large-vessel thrombosis in the venous system (deep vein thrombosis, splanchnic vein thrombosis, pulmonary embolism) or the arterial system (including acute myocardial infarction, ischemic stroke, and acute limb ischemia), have been described.[4] However, existing epidemiological studies suggest that venous thromboembolism (VTE) is the predominant form of thrombotic events, with reported rates in the literature being variable between 7% up to more than 80% (upon routine screening of critically ill patients).[5] [6] [7]

In this setting, the optimal strategies for prevention of thrombotic events and choice of antithrombotic agents for management of pre-existing or new thrombotic events in patients with COVID-19 are of utmost importance. Herein, we provide a succinct summary of potential pharmacological options for the treatment and prevention of thrombosis in patients with COVID-19.



Publication History

Article published online:
20 August 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020 . Accessed on June 1, 2020
    Google Scholar
  • 3 Gupta A, Madhavan MV, Sehgal K. et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020 (in-press)
    Google Scholar
  • 4 Bikdeli B, Madhavan MV, Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020; 75 (23) 2950-2973
    CrossrefPubMedGoogle Scholar
  • 5 Goyal P, Choi JJ, Pinheiro LC. et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020; 382 (24) 2372-2374
    Google Scholar
  • 6 Ren B, Yan F, Deng Z. et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. Circulation 2020; ; (e-pub ahead of print) DOI: 10.1161/CIRCULATIONAHA.120.047407.
    CrossrefPubMedGoogle Scholar
  • 7 Bikdeli B, Madhavan MV, Gupta A. et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; ; (e-pub ahead of print) DOI: 10.1055/s-0040-1713152.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Driggin E, Madhavan MV, Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol 2020; 75 (18) 2352-2371
    CrossrefPubMedGoogle Scholar
  • 9 Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. Semin Thromb Hemost 2019; 45 (05) 490-501
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Bangalore S, Sharma A, Slotwiner A. et al. ST-segment elevation in patients with Covid-19—a case series. N Engl J Med 2020; ; (e-pub ahead of print) DOI: 10.1056/nejmc2009020.
    CrossrefPubMedGoogle Scholar
  • 11 Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: do heparins have direct anti-inflammatory effects?. Thromb Haemost 2017; 117 (03) 437-444
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost 2020; 46 (03) 379-382
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 14 Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2019; 2019 (00) 2019-2020
    PubMedGoogle Scholar
  • 15 Cohen AT, Spiro TE, Büller HR. et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
    CrossrefPubMedGoogle Scholar
  • 16 Spyropoulos AC, Lipardi C, Xu J. et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. Clin Appl Thromb Hemost 2019; 25: 1076029619886022 (e-pub ahead of print) DOI: 10.1177/1076029619886022.
    CrossrefPubMedGoogle Scholar
  • 17 Moore HB, Barrett CD, Moore EE. et al. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?. J Trauma Acute Care Surg 2020; 88 (06) 713-714
    CrossrefPubMedGoogle Scholar
  • 18 Hardaway RM, Williams CH, Marvasti M. et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990; 18 (12) 1413-1418
    CrossrefPubMedGoogle Scholar
  • 19 Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med 1998; 25 (02) 184-188
    CrossrefPubMedGoogle Scholar
  • 20 Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg 2001; 67 (04) 377-382
    CrossrefPubMedGoogle Scholar
  • 21 Liu C, Ma Y, Su Z. et al. Meta-analysis of preclinical studies of fibrinolytic therapy for acute lung injury. Front Immunol 2018; 9: 1898
    CrossrefPubMedGoogle Scholar
  • 22 Li H, Liu L, Zhang D. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395 (10235): 1517-1520
    CrossrefPubMedGoogle Scholar
  • 23 Boyle AJ, Di Gangi S, Hamid UI. et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care 2015; 19 (01) 109
    CrossrefPubMedGoogle Scholar
  • 24 Kor DJ, Carter RE, Park PK. et al; US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A). Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department the LIPS-a randomized clinical trial. JAMA 2016; 315 (22) 2406-2414
    CrossrefPubMedGoogle Scholar
  • 25 Sexton TR, Zhang G, Macaulay TE. et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl Sci 2018; 3 (04) 435-449
    CrossrefPubMedGoogle Scholar
  • 26 Aungraheeta R, Conibear A, Butler M. et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood 2016; 128 (23) 2717-2728
    CrossrefPubMedGoogle Scholar
  • 27 Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res 2020; 158: 104950
    CrossrefPubMedGoogle Scholar
  • 28 Tonew E, Indulen MK, Dzeguze DR. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol 1982; 26 (03) 125-129
    PubMedGoogle Scholar
  • 29 Li Z, Li X, Huang Y-Y. et al. FEP-based screening prompts drug repositioning against COVID-19. bioRxiv 2020; DOI: 10.1101/2020.03.23.004580.
    CrossrefPubMedGoogle Scholar
  • 30 Liu X, Li Z, Liu S. et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B 2020; ; (e-pub ahead of print) DOI: 10.1016/j.apsb.2020.04.008.
    CrossrefPubMedGoogle Scholar
  • 31 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847 Doi: 10.1111/jth.14768
    CrossrefPubMedGoogle Scholar
  • 32 Schreiber K, Breen K, Parmar K, Rand JH, Wu XX, Hunt BJ. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford) 2018; 57 (01) 120-124
    CrossrefPubMedGoogle Scholar
  • 33 Magro C, Mulvey JJ, Berlin D. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; (e-pub ahead of print) DOI: 10.1016/j.trsl.2020.04.007.
    CrossrefPubMedGoogle Scholar
  • 34 Coronavirus Disease. 2019 (COVID-19) Treatment Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/ . Accessed June 3, 2020
    Google Scholar
  • 35 Genentech's arthritis drug tocilizumab shows promise in Covid-19 trial. Available at: https://www.clinicaltrialsarena.com/news/french-early-trial-tocilizumab-covid-19/ . Accessed June 3, 2020
    Google Scholar